Pathos AI makes successful takeover bid for Rain Oncology

2023-12-14

并购

Pathos AI is acquiring Rain Oncology for $1.16 in cash per share plus a non-tradable contingent value right for potential cash payments of up to $0.17 per share, just a few months after investment group Tang Capital Management’s takeover bid failed.

Rain will operate as a subsidiary of Pathos, with the acquisition expected to close in January, though the offer depends on several conditions, including the availability of at least $49.6 million in cash and cash equivalents.

Pathos AI makes successful takeover bid for Rain Oncology

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

Pathos AI, Inc.